Search research articles
Contact Us
Filters
Showing results (81-90 of 90) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 90 results.
Cell Communication and Signaling : CCS
|
January 6, 2026
The food grade bacterium Lactobacillus helveticus VEL12193 promotes autophagy by releasing membrane vesicles
Marie-Agnès Bringer, Simon Manceau, Jana Al Azzaz, et al.
Bulletin Du Cancer
|
November 26, 2015
[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria]
Vincent Launay-Vacher, Nicolas Janus, Philippe Beuzeboc, et al.
The European Respiratory Journal
|
March 17, 2018
Cost-effectiveness of <i>KRAS</i>, <i>EGFR</i> and <i>ALK</i> testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study
Sandrine Loubière, Alexandre Drezet, Michèle Beau-Faller, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 1, 2024
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
Aurélie Swalduz, Michèle Beau-Faller, David Planchard, et al.
Pediatric Blood & Cancer
|
March 16, 2026
Carcinomas and Carcinoid Tumors of the Lungs and Bronchi in Children and Adolescents: The EXPeRT Recommendations
Michael Abele, Calogero Virgone, Michaela Kuhlen, et al.
Oncotarget
|
April 23, 2021
High <i>in vitro</i> and <i>in vivo</i> synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
Elodie Montaudon, Rania El Botty, Sophie Vacher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 21, 2023
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018
Olivier Bylicki, Pascale Tomasini, Gervais Radj, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 18, 2012
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2)
Jacques Cadranel, Audrey Mauguen, Michele Faller, et al.
Clinical Lung Cancer
|
July 2, 2020
Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients
Elisa Gobbini, Anne Claire Toffart, Maurice Pérol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2022
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 90) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 90 results.
Cell Communication and Signaling : CCS
|
January 6, 2026
The food grade bacterium Lactobacillus helveticus VEL12193 promotes autophagy by releasing membrane vesicles
Marie-Agnès Bringer, Simon Manceau, Jana Al Azzaz, et al.
Bulletin Du Cancer
|
November 26, 2015
[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria]
Vincent Launay-Vacher, Nicolas Janus, Philippe Beuzeboc, et al.
The European Respiratory Journal
|
March 17, 2018
Cost-effectiveness of <i>KRAS</i>, <i>EGFR</i> and <i>ALK</i> testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study
Sandrine Loubière, Alexandre Drezet, Michèle Beau-Faller, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 1, 2024
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
Aurélie Swalduz, Michèle Beau-Faller, David Planchard, et al.
Pediatric Blood & Cancer
|
March 16, 2026
Carcinomas and Carcinoid Tumors of the Lungs and Bronchi in Children and Adolescents: The EXPeRT Recommendations
Michael Abele, Calogero Virgone, Michaela Kuhlen, et al.
Oncotarget
|
April 23, 2021
High <i>in vitro</i> and <i>in vivo</i> synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
Elodie Montaudon, Rania El Botty, Sophie Vacher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 21, 2023
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018
Olivier Bylicki, Pascale Tomasini, Gervais Radj, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 18, 2012
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2)
Jacques Cadranel, Audrey Mauguen, Michele Faller, et al.
Clinical Lung Cancer
|
July 2, 2020
Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients
Elisa Gobbini, Anne Claire Toffart, Maurice Pérol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2022
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, et al.
Page
of 9